Sun Pharma Advanced Research Company Limited announced that the Company has incorporated a WOS namely "SPARCLIFE Inc." in Delaware, US with effect from September 25, 2023. The total number of shares of stock which the corporation shall have authority to issue is 5,000 shares of Common Stock, par value USD 0.001. Paid up Share Capital: 50 Shares of Common Stock of value USD 0.001 each at the consideration of USD 50,000.

Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity). The main object of the Company is to obtain the services of the WOS which would engage a team of seasoned professionals based in US who coordinates, reviews and monitors the global clinical trials being conducted through various CROs in US by the Company.